SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--OneWorld Health (OWH) announced that it will participate in a major consortium project aimed to boost strategies for control and eventual elimination of visceral leishmaniasis (VL or kala-azar) in India and Bangladesh, where the disease burden is among the world’s highest. OneWorld Health received 1.9 million USD as part of a larger grant for the project led by the Drugs for Neglected Diseases initiative (DNDi). Also collaborating in this consortium is the Special Programme for Research Training in Tropical Diseases (TDR). The four-year long initiative aims to establish and implement new treatment modalities to advance kala-azar elimination in South Asia’s most endemic regions.
